Wieczorek Paweł, Bałut-Wieczorek Marta, Jasinski Milosz, Szabłoński Waldemar, Antczak Andrzej
Department of Urology, University Hospital in Zielona Góra, Poland.
Department of Oncological Urology, Oncology Centre in Bydgoszcz, Poland.
Cent European J Urol. 2018;71(4):399-403. doi: 10.5173/ceju.2018.1696. Epub 2018 Sep 24.
There is a need for a new biochemical marker of aggressive prostate cancer (PCa). Inosine monophosphate dehydrogenase 2 (IMPDH2) is a candidate for such a marker - its activity is increased in certain tumors and neoplastic cell lines, including PCa, and may correlate with cancer aggressiveness.
IMPDH2 levels were measured in blood samples from 34 PCa patients. The results were analyzed and correlated with prostate-specific antigen (PSA), digital rectal examination (DRE), Gleason score, risk groups according to d'Amico and metastatic disease. Twenty healthy (non-PCa) patients served as the control group.
There was no significant difference in IMPDH2 level between the PCa and control group, and no significant correlation between PSA and IMPDH2. IMPDH2 levels were significantly higher in the DRE (+) patients (148.5 ±174.8 vs. 33.4 ±46.4, p <0.05), in patients with metastatic disease (100.1 ±139.0 vs. 25.3 ±25.9, p <0.05) and in the high-risk group according to d'Amico (93.4 ±129.2 vs. 18.8 ±10.4, p <0.05). There was a significant correlation between the Gleason score and IMPDH2.
These results suggest that IMPDH2 is a promising candidate as a biomarker for those with advanced PCa and those at high risk of progression towards advanced PCa.
侵袭性前列腺癌（PCa）需要一种新的生化标志物。肌苷单磷酸脱氢酶2（IMPDH2）是这类标志物的一个候选者——其活性在某些肿瘤和肿瘤细胞系（包括PCa）中升高，并且可能与癌症侵袭性相关。
检测了34例PCa患者血样中的IMPDH2水平。分析结果并将其与前列腺特异性抗原（PSA）、直肠指检（DRE）、Gleason评分、根据达米科分类的风险组以及转移性疾病进行关联。20名健康（非PCa）患者作为对照组。
PCa组和对照组之间IMPDH2水平无显著差异，PSA与IMPDH2之间也无显著相关性。DRE（阳性）患者（148.5±174.8对33.4±46.4，p<0.05）、有转移性疾病的患者（100.1±139.0对25.3±25.9，p<0.05）以及根据达米科分类的高危组患者（93.4±129.2对18.8±10.4，p<0.05）的IMPDH2水平显著更高。Gleason评分与IMPDH2之间存在显著相关性。
这些结果表明，IMPDH2作为晚期PCa患者以及有进展为晚期PCa高风险患者的生物标志物是一个有前景的候选者。
